

[Azathioprine](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics 8.1. Immunomodulators for non-malignant disease](#)

ATC codes: [L04AX01](#)

EMLc

Indication

Failure or rejection of transplanted organs or tissues ICD11 code: [NE84](#)

INN

Azathioprine

Medicine type

Chemical agent

List type

Complementary

Formulations

Parenteral > General injections > IV: 50 mg in vial powder for injection (as sodium salt) ; 100 mg in vial powder for injection (as sodium salt) (EMLc)

Oral > Liquid: 10 mg per mL (EMLc)

Oral > Solid > tablet: 25 mg ; 50 mg (scored) (EMLc)

EML status history

First added in 1979 ([TRS 641](#))

Changed in 1984 ([TRS 722](#))

Changed in 2002 ([TRS 914](#))

Changed in 2003 ([TRS 920](#))

Changed in 2007 ([TRS 950](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Azathioprine](#)

DrugBank

[Azathioprine](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of new formulations of azathioprine (oral liquid 10 mg/mL, powder for injection 50 mg, and tablet 25 mg) to the EMLc.